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ABSTRACT

A method of testing bacterial cells for antimicrobial susceptibility includes preparing a suspension of the bacterial cells
in a non-nutrient medium, mixing with the suspension an
antimicrobial, a carbohydrate usable by the bacterial cells,
metallic nanoparticles, and a lectin, and incubating the mixture while monitoring a parameter of the nanoparticles
responsive to use of the carbohydrate by the bacterial cells.
More broadly stated, the invention includes a method of testing an agent for its effect on cell metabolism by preparing a
suspension of cells in a non-nutrient medium, mixing the
suspension with the agent, adding a carbohydrate usable by
the cells, metallic nanoparticles, and a lectin with binding
specificity for the added carbohydrate, and monitoring a
nanoparticle parameter responsive to the cells.
13 Claims, 13 Drawing Sheets
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NANOPARTICLE-MEDIATED METHODS
FOR ANTIMICROBIAL SUSCEPTIBILITY
TESTING OF BACTERIA

testing the effect of a treatment agent upon a cell's metabolism. The methods of the invention are eminently applicable
to antibiotic susceptibility testing of bacterial isolates. Additionally, the disclosed methods may also be employed to test
an agent for its effect on the metabolism of cells, whether the
cells are bacterial cells or the cells of higher organisms,
including mammalian cells in culture.
Significant efforts have been made for the development of
biosensors, capable of detecting biological targets, such as
proteins, nucleic acids, viruses and bacteria. The aggregation
of metallic nanoparticles, induced by specific biomolecular
interactions, has been employed in the development of simple
and sensitive biosensors with potential applications in immunoassays. Noble metal nanoparticles, in particular gold nanoparticles (AuNPs), have recently been the focus of extensive
studies in this field, due to their extraordinary optical and
electronic properties.
Gold nanoparticles exhibit a strong surface plasmon resonance band, as a consequence of collective oscillations of the
surface electrons, which are induced by the incident electromagnetic radiation. On the other hand, iron-oxide-based
magnetic nanocrystals have been widely used in a variety of
biomedical applications, for example, in diagnostics, magnetic resonance imaging (MRI) and magnetically-guided
site-specific drug delivery systems. Notably, the use of magnetic nanoparticles in the fast and reliable detection of a
specific bacterium in complex biological media (blood and
milk) has been recently reported.
The working mode of these nanosensors relies on the phenomenon where in the presence of a target these nano sensors
self-assemble, that is, they agglutinate. The induction of
nano-assembly formation results in a concomitant significant
change in the surface plasmonresonance of noble metal nanoparticles (either gold or silver). In the case of magnetic nanoparticles (such as iron oxide), there is a dramatic effect on the
spin-spin relaxation time (T2) of neighboring water molecules' protons.
Based on the above behavior, we have developed a quick
and facile assay for the assessment of antimicrobial susceptibility, using either gold or iron oxide nanoparticles (IONPs)
coated with a polysaccharide layer preferably but not exclusively composed of polymerized dextran. Particularly, the
detection principle relies on the fact that in the presence of an
effective antibiotic (bactericidal or bacteriostatic) and at
inhibitory concentrations, there is suppression of the bacterial
metabolism and reduction in nutrient uptake (i.e. carbohydrates). Hence, the concentration of the nutrients, such as
starch and other carbohydrates, remains higher when compared to those under non-inhibitory antibiotic concentrations,
antibiotic resistance, antibiotic incompetence or absence of
an inhibitory compound. Therefore, after incubating the
nanoparticle-specimen suspension in the presence of Concanavalin A (Con A), it is possible to assess the metabolic
activity of the cells, based on the concentration of carbohydrate remaining, which is related to the changes in T2 or
surface plasmon resonance band.
The presently described methods have several advantages
over existing methodology. The present methods are facile
and cost effective. Preparation of the nanoparticles does not
require the use of toxic reagents, and therefore the synthesized nanoparticles are environmentally friendly and nontoxic to the assay's user. Good stability of the resulting particles over prolonged storage in water, phosphate buffered
saline and citrate buffer, makes them suitable for use at the
points-of-care and under harsh conditions. The resulting gold
and iron oxide particles can be concentrated using ultrafiltration devices without inducing agglomeration of the nanopar-

RELATED APPLICATION
This application claims priority from co-pending provisional application Ser. No. 60/982,529, which was filed on 25
Oct. 2007, and which is incorporated herein by reference in its
entirety.
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STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH
This invention was made with govermnent support under
KOi CAI 01781 awarded by the National Institutes of Health.
The government has certain rights in the invention.
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FIELD OF THE INVENTION
The present invention relates to the field of infectious diseases and, more particularly, to methods of determining the
susceptibility of cells, particularly bacterial cells, to a potential treatment agent such as an antibiotic.
BACKGROUND OF THE INVENTION
The identification and administration of an effective antimicrobial agent is of the utmost importance in clinical and
point-of-care patient settings. Specifically, with the emergence of multi-drug resistant bacterial strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multiply
drug resistant tuberculosis (XDR-TB), identifying the most
effective antibiotic and administering it to the patient at concentrations that will kill or inhibit bacterial growth without
undermining the patient's health is important.
Currently, the assessment of antimicrobial susceptibility
relies on the isolation of the microorganism, followed by an
attempt to grow the pathogen in the presence of various antibiotic agents and different concentrations thereof. A major
problem with this approach is that it requires at least 24 hours
in order to provide qualitative and quantitative information
associated with the effectiveness of the antibitiotic. In the
meantime, even though physicians will institute treatment on
clinical grounds and without waiting for the lab results, the
patient might face severe complications and worsening of
his/her pathological condition due to growth and pathogenesis induced by the microorganism and inability of the
immune system to respond in an effective way. As mentioned
before, typically, physicians caring for the hospitalized
patient must start antibiotic treatment based only on experience and clinical hunches, since the results of in vitro antibiotic susceptibility tests will not be available for 48-72 hours
after initial cultures are taken.
Therefore, the need of fast and accurate antimicrobial susceptibility assessment modalities remains, even in this day of
modern medical advances. Additionally, apart from clinical
and point-of-care diagnostics, the pharmaceutical industry is
under pressure to continue development of novel, sensitive
and rapid antimicrobial susceptibility assays. Hence, having
methods to facilitate high-throughput screening of candidate
antibiotics, while using small sample volumes, could reduce
the costs associated with drug development and expedite the
drug development process.
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With the foregoing in mind, the present invention advantageously provides a novel, rapid and sensitive method for
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ticles. Polysaccharide-coated gold and iron oxide nanoparticles can be used to assess bacterial metabolism fast and
accurate with available instrumentation, based on the consumption of carbohydrates in the culture medium. Dextrancoated gold and iron oxide nanoparticles can be used to assess
antimicrobial susceptibility and an antibiotic's minimum
inhibitory concentration (MIC), based on the consumption of
carbohydrates by the microorganisms, without relying on the
expression of reporter genes. Dextran-coated gold and iron
oxide nanoparticles can fast and reliably assess the state of
bacterial metabolism and antimicrobial susceptibility, requiring a fraction of the time needed by such standard methods as
the turbidity test, disc diffusion assay, and plate growth).
Dextran-coated gold and iron oxide nanoparticles can determine bacterial metabolism and antimicrobial susceptibility
using small sample volumes (about 10 µL ), which is useful for
the screening of expensive antimicrobial agents and growth in
specialized culture media.
Dextran-coated gold and iron oxide nanoparticles can
assess antimicrobial susceptibility in an affordable, highthroughput setting, supporting expedited decision making.
The nanoparticles of the present invention can be used in the
field and at the point-of-care to assess antimicrobial susceptibility, as they are stable over a wide range of temperatures
and do not require special storage conditions. The dextrancoated nanoparticles can determine antimicrobial susceptibility using bacteria isolated from clinical and environmental
specimens, without the need to use engineered or sensitive
strains. The dextran-coated nanoparticles can facilitate antimicrobial susceptibility, without the use of radioactive or
hazardous materials. etermination of antimicrobial activity
can be performed with either a simple UV-Vis spectrophotometer or a miniaturized, portable NMR, using gold and iron
oxide nanoparticles respectively.
Accordingly, the present invention provides a method of
testing bacterial cells for antimicrobial susceptibility. The
method comprises preparing a suspension of the bacterial
cells in a non-nutrient medium and mixing with the suspension an antimicrobial, a carbohydrate usable by the bacterial
cells, metallic nanoparticles, and a lectin. The method continues by incubating the mixture while monitoring a parameter of the nanoparticles responsive to use of the carbohydrate
by the bacterial cells.
More broadly stated, the invention discloses a method of
testing an agent for its effect on cell metabolism. This
embodiment of the invention includes preparing a suspension
of cells in a non-nutrient medium, mixing the suspension with
the agent, adding a carbohydrate usable by the cells, metallic
nanoparticles, and a lectin with binding specificity for the
added carbohydrate, and monitoring a nanoparticle parameter responsive to the cells.
Yet another variation in the present invention includes a
method of monitoring the metabolism of cells. This method
comprises preparing a suspension of the cells in a non-nutrient medium, mixing the suspension with metallic nanoparticles bearing a lectin, adding to the suspension a carbohydrate metabolizable by the cells and monitoring the
nanoparticles for a parameter responsive to metabolism of the
carbohydrate by the cells.

tion with the accompanying drawings, presented for solely
for exemplary purposes and not with intent to limit the invention thereto, and in which:
FIG. 1 is a TEM image of dextran-coated (a) gold and (b)
iron oxide nanoparticles according to an embodiment of the
present invention; the TEM images show that the gold nanoparticles are spherical, whereas the iron oxide particles are
rods;
FIG. 2 shows a proposed model for gold nanoparticle
(AuNP) mediated antimicrobial susceptibility assessment; in
the absence ofbacterial metabolism (B) or under sterile conditions (C), addition ofConcanavalinA (ConA) results in the
formation of extensive nanoassemblies and large shifts in the
surface plasmon band oftheAuNPs due to the contribution of
free carbohydrates; bacterial metabolic activity is associated
with lower shifts in the plasmonic band due to the formation
of smaller nanoassemblies; the trend described herein is predicted to be similar when other metallic nanoparticles are
used (for instance, silver) observing similar changes in surface plasmon peak; in addition, the same behavior is observed
when magnetic polysaccharide-coated nanoparticles (such as
iron oxide) are used, however in this case changes in water
relaxation time are observed;
FIG. 3 illustrates the UV-Visible spectra of gold nanoparticles in non-assembled conditions;
FIG. 4 depicts that AuNPs' spectral characteristics are
independent of the antibiotic concentration, under Concanavalin A-induced clustering;
FIG. 5 shows that in the absence ofConA, theAuNPs were
in a non-assembled state, exhibiting the same spectral characteristics, regardless of the presence of bacteria and antibiotic; samples with ampicillin (64, 8, and 2 µg) and the bacterial growth control (0 µg ampicillin) contained aliquots from
liquid cultures initially inoculated with 10 6 CFU of E. coli;
FIG. 6 presents the shift of the gold nanoparticles' surface
plasmon band at (A) low (non-inhibitory, 2 µg) and (B) high
(inhibitory, 64 µg) ampicillin concentrations;
FIG. 7 shows the shift of the gold nanoparticles' surface
plasmon band at low (non-inhibitory, 2 µg) and high (inhibitory, 64 µg) ampicillin concentrations, while using higher
amount of AuNPs ( 50: 50 AuNP:dH20 v:v );
FIG. 8 is a determination of the MIC using (A) the surface
plasmon peak shift of Au NPs and (B) the turbidity method
(original photograph, numbers indicate the amount of ampicillin);
FIG. 9 is a determination of MIC in high-throughput format using Au-NP and Con A; purple squares indicate absence
of bacterial metabolism, green areas demonstrate inhibition
of bacterial metabolism, and red wells show active bacterial
metabolism, similar to the data trend of Table 1; Group (a)
Sterile Mueller-Hinton (MH) broth, (b) E. coli (10 6 CFU)
grown in the absence ofampicillin, (c) heat-inactivatedE. coli
(10 6 CFU) in MH broth, (d) and (e) E. coli (10 6 CFU) grown
in the presence of 64 and 2 µg ampicillin, respectively; following wells include replications of these groups, obeying the
above pattern; Group (f) consists of additional control
samples, similar to (a);
FIG. 10 shows dose-dependent changes in T2 of dextrancoated IONPs in the presence of Con A after a 30-minute
incubation at room temperature; sigmoidal fit was applied
with an R2=0.99 (OriginPro 7.5); similar results were
obtained after 0-, 90- and 150-minute incubations;
FIG. 11 shows that in the absence of ConA, the IO NPs
were in a non-assembled state, exhibiting the same T2,
regardless of the presence of bacteria. 1; water, 2; sterile
medium (with starch), 3; sterile medium (no starch), 4; 102
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apparent as the description proceeds when taken in conjunc-
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CFU of E. coli, 5; 103 CFU of E. coli, 6; 104 CFU of E. coli,
7; 105 CFU of E. coli, 8; 10 6 CFU of E. coli, 9; 10 8 CFU of E.
coli, 1O; 109 CFU of E. coli;
FIG. 12 shows dose-dependent changes in T2 of IONPs
associated with starch consumption, due to various degrees of
bacterial loads; the graph depicts data obtained after a
30-minute incubation at room temperature, in the presence of
Concanavalin A; sigmoidal fit was applied with an R2=0.99
(OriginPro 7.5); similar results were obtained after 0- and
90-minute incubations;
FIG. 13 depicts that the behavior ofIONPs is independent
of the bacterial population, but it is dependent of active bacterial metabolism; the graph depicts data obtained after a
30-minute incubation at room temperature, in the presence of
Con A; linear fit was applied with an R2=0.14 (OriginPro
7.5); similar results were obtained after 0-, 90- and 150minute incubations;
FIG. 14 indicates that in the absence ofConA, the IONPs
exhibited the same T2, regardless of the presence of bacteria
and antibiotic, 1; water, 2; sterile medium (with starch), 3;
sterile medium (no starch), 4; 64 µg ampicillin, 5; 8 µg ampicillin, 6; 2 µg ampicillin; 7; 1 µg ampicillin, 8; 0 µg ampicillin;
FIG. 15 is a determination of the minimum inhibitory
concentration using (A) the changes in spin-spin relaxation
times (iH2) and (B) the turbidity method (original photograph, numbers indicate the amount of ampicillin); a similar
trend was observed after 0- and 45-minute incubation at room
temperature; the dotted line indicates the threshold of the
drug's successful inhibition;
FIG. 16 is a determination of the minimum inhibitory
concentration of Shigella sonnei using the changes in spinspin relaxation times (li. T2) after a 30-min incubation at 25°
C.; the dotted line indicates the threshold of the drug's successful inhibition;
FIG. 17 shows an assay of antibiotic resistance of Serratia
marcescens using the changes in spin-spin relaxation times
(li.T2) after a 30-min incubation at 25° C.; the dotted line
indicates the threshold of the drug's successful inhibition;
FIG. 18 shows a schematic representation of the assessment of antimicrobial susceptibility using Concanavalin
A-conjugated polysaccharide nano sensors using a silica coating where the direct conjugation of Con A to the capping
matrix results in a non-competition based assay format;
FIG. 19 shows kinetic profiles of the dextran-coated
nano sensors and Con-A conjugated nano sensors where point
A is the end-point of the dextran-coated nanosensors and
point Bis the end-point of of the Con-A conjugated nano sensors; and
FIG. 20 shows the antimicrobial susceptibility in blood
using Con-A conjugated nano sensors in which (A) is a graph
of the determination of E Coli 's ampicillin MIC in blood and
(B) is a graph of the determination of Serratia marcescens'
drug resistance in blood with the Con-A conjugatednanosensors five minutes after addition of a bacterial aliquot into the
nanoparticle solution (Means±SE; p<0.05).

testing of the present invention, suitable methods and materials are described below. Any publications, patent applications, patents, and other references mentioned herein are
incorporated by reference in their entirety. In case of conflict,
the present specification, including any definitions, will control. In addition, the materials, methods and examples given
are illustrative in nature only and not intended to be limiting.
Accordingly, this invention may be embodied in many different forms and should not be construed as limited to the illustrated embodiments set forth herein. Rather, these illustrated
embodiments are provided so that this disclosure will be
thorough and complete, and will fully convey the scope of the
invention to those skilled in the art. Other features and advantages of the invention will be apparent from the following
detailed description, and from the claims.
Portions of the disclosure made herein have been published
in the scientific literature, as follows. Dextran-Coated Gold
Nanoparticles for the Assessment of Antimicrobial Susceptibility; S. Nth, C. Kaittanis, A. Tinkham and J. M. Perez;
Analytical Chemistry, 2008, 80, 1033-1038 (published on
Web Jan. 17, 2008). Rapid Nanoparticle-Mediated Monitoring of Bacterial Metabolic Activity and Assessment of Antimicrobial Susceptibility in Blood with Magnetic Relaxation;
C. Kaittanis, S. Nath and J. M. Perez; Plos One, September
2008, Vol. 3, Issue 9, e3253 (an Internet publication available
at www.plosone.org). As noted above, both of these scientific
articles are incorporated herein by reference in their entirety
and are intended to constitute part of this disclosure.
Bacterial Cultures
In order to investigate if the dextran-coated iron oxide
nanoparticles can monitor the starch utilization due to bacterial metabolic activity, different populations of Escherichia
coli (strain 8739 fromATCC) were grown in starch-containing MH broth (DIFCOTM, BD) for 2 hours at 37° C. For
determination of the minimum inhibitory concentration,
Escherichia coli (106 CFU), Serratia marcescens (ATCC,
106 CFU) and Shigella sonnie (strain 9290 from ATCC,
106CFU) were grown in a starch-containing MH broth (DIFCOTM, BD), for 2 hours at 37° C. in the presence or absence
of ampicillin. For determination of MIC in blood, bacterial
stocks (106 CFU) were grown in the presence or absence of
ampicillin in a 5%-blood-supplemented starch-containing
MH broth, for 2 hours at 3 7° C. Defibrinated sheep blood was
obtained from the Colorado Serum Company, simulating bacterial isolation and growth in typical blood agar plates. For
studies requiring heat inactivation, E. coli bacteria wee autoclaved in the culture tubes for 10 minutes. Upon incubation or
inactivation, all bacterial stocks were placed in a Fisher
Isotemp freezer (Fisher Scientific, Hampton, N.H.), until further use.
Nanoparticle Synthesis
Reagents.
All the reagents used were of AR (Analytical Reagent)
grade. Nitrogen-purged double-distilled water was used
throughout the reaction. Iron salts, FeC1 2 .4H 2 0 and
FeC1 3 .6H 2 0, were obtained from Fluka. Dextran (MW 10
kDa) was received from Amersham. TEOS: tetraethylorthosilicate (Fluka), APTS: 3-(amino-propyl)triethoxysilane (Aldrich) and THPMP: 3-(trihydroxysilyl)propylmethyl-phosphonate (Gelest Inc) were used as received from the suppliers.
Synthesis ofDextran-Coated Gold Nanoparticles (AuNPs):
Gold nanoparticles were synthesized by boiling a mixture
of aqueous solution of gold chloride (HAuC1 4 ) and dextran
(10 k). Explicitly, 1 ml HAuC1 4 (10- 2 M) was mixed with
aqueous solution of dextran (10 gin 100 ml H 2 0) and heated
to boil on a hot plate. The solution turned piuk within 10 min
and exhibits a UV-visible band at 531 nm, attributed to the
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The present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
which preferred embodiments of the invention are shown.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or

60

65

US 9,057,094 Bl
7

8

formation of gold nanoparticles. Finally, the gold nanoparticles were filtered and washed several times with distilled
water through an Ami con cell (Millipore ultrafiltration membrane YM-30 k) to remove the free dextran molecules.
Synthesis of Aminated Silica Coated IO NPs:
The aminated silica-coated iron oxide nanoparticles were
prepared using a previously published protocol, with modifications in order to yield stable nanoparticles via a water-based
synthesis. Specifically, iron oxide nanocrystals were formed
via the alkaline precipitation method, by mixing a solution of
iron salts (0.202 g FeC1 2 .4H 2 0, 0.488 g FeCly6H 2 0, 88.7 µL
HCl in 2 mL distilled water) with an armnonium hydroxide
solution (830 µl NH4 0H in 15 mL distilled water). Then, 20
seconds after the initiation of the iron oxide nanocrystal formation, a TEOS-THPMP-APTS solution was added (6180
µL THPMP, 2680 µL TEOS, 670 µL APTS) under continuous
vortexing. The as-synthesized nanoparticle suspensions were
centrifuged to remove large particles. Both the amino-silicaand dextran-coated nanoparticles were washed several times
with distilled water and concentrated through an Amicon
8200 cell (Millipore Ultrafiltration membrane YM-30 k).
Finally, the nanoparticle suspensions were stored at 4° C.
until further use.
ConcanavalinA was conjugated to the to aminated silicacoated iron oxide nanoparticles in the following manner. Two
milliliters of aminated silica coated iron oxide nanoparticles
(R2=225 mM- 1 s-1, [Fe]=0.47 mg/ml) were used for the conjugation of Con A to the nanoparticles' surface. Initially, in 1
mL of cold MES buffer (0.1 M, pH 6.0) 4.8 mg EDC (Pierce)
and 3 mg NHS (Pierce) were dissolved. Then, 2 mg of lyophilized Con A (Type V, Sigma) were dissolved in 2 mL cold
MES buffer (0.1 M, pH 6.0). Subsequently, the Con A solution was mixed with the EDC/NHS solution, followed by a
3-minute low-speed rotary mixing at room temperature.
Finally, the aminated silica-coated iron oxide nanoparticles
were added to the Con A (amine-reactive NHS-ester form)
solution, followed by periodical rotary mixing at low speed
and storage at 4° C. The resulting Con A-conjugated silicacoated iron oxide nanoparticles were purified from any
unbound protein via magnetic separation using an MES
buffer-equilibrated (0.1 M) LS25 MACSH colunm (Miltenyi
Biotec).
Synthesis ofDextran-Coated IO Nanoparticles (IO NPs):
A mixture of iron salts 0.203 g FeC1 2 .4H 2 0 and 0.488 g
FeCl 3 .6H 2 0 inHCl solution (88.7 µ112 NHCl in2ml water)
was added to NH4 0H (830 µl in 15 ml N 2 purged deionized
water) and stirred on a digital vortex mixer for 10 sec. Then,
an aqueous solution of dextran ( 5 gin 10 ml water) was added
to the mixture and stirred for 1 hr. Finally, the entire mixture
was centrifuged for 30 minutes to remove large particles,
whereas the supernatant was collected, filtered, and washed
several times with distilled water through an Amicon cell
(Millipore ultrafiltration membrane YM-30 k) to remove any
free dextran molecules.
Dextran-Coated Gold Nanoparticles for Antimicrobial Susceptibility:
In order to determine if noble metal nanoparticles, like Au
NPs', surface plasmon resonance band is affected by the
presence of complex growing media, we added into the nanoparticle suspension (400 µLAu NPs in 600 µL distilled water)
either 10 µL distilled water (black line) or 10 µL MuellerHintro (MH) broth containing starch (red line). After examination of the samples on a Cary 300 UV-Visible spectrophotometer (Varian Inc.), both samples exhibited the same
surface plasmon peak (FIG. 3). This supported the hypothesis

that the nanoparticles' surface plasmon band would not be
affected by the presence of media, under non-assembled conditions.
Subsequently, we determined if the presence of antibiotics
in the growing media had any effects on the shift of the surface
plasmon band, under assembled conditions. Specifically, 10
µL aliquots ofMH broth, with varying amounts of ampicillin,
were incubated with gold nanoparticles (400 µL Au NPs in
600 µL distilled water) for 30 minutes at room temperature in
the presence ofl 0 µL ConcanavalinA (1 µg/µL). The samples
were examined on a Cary 300 UV-Vis spectrophotometer,
and the shift of the surface plasmon band was determined.
The obtained data indicated that the shift of the surface plasmon resonance band is independent of the antibiotic's concentration, under concanavalin-induced assembled conditions (FIG. 4).
Considering that Con A has affinity towards molecules
with carbohydrate moieties, we reasoned that any variations
in the carbohydrate concentrations should be observable
using a known amount of dextran-coated nanoparticles and
Con A, based on the surface plasmon band shift. Hence, the
shift of the gold nanoparticles' surface plasmon resonance
band should have depended on bacterial metabolism and corresponded to the levels of free carbohydrates in the solution.
To study this, E. coli (10 6 CFU) were incubated for 2 hours at
3 7° C. in MH broth, in the presence of various concentrations
of ampicillin. Then, 10 µL aliquots of these samples were
added into the Au NPs suspension, as stated above. Despite
the presence of bacteria and antibiotic, the samples exhibited
identical absorption spectra, under non-assembled conditions
(FIG. 5).
After addition of Con A and a 30-minute incubation at 25°
C., distinct spectral differences were observed. Interestingly,
under a small, presumably non-inhibitory, antibiotic concentration the shift in the band was low, compared to the sterile
control (FIG. 6A). A similar trend was also observed in the
sample where bacteria grew in the absence of the antibiotic.
However, under high, most likely inhibitory, concentration
the shift was large with a broader shoulder, resembling the
sterile control (FIG. 6B). This behavior was due to the higher
amount of free carbohydrates that have not been utilized by
the bacteria as their metabolism was suppressed, promoting
extensive concanavalin-induced Au NP clustering. Analogous results were obtained when higher concentrations ofAu
NPs were used (FIG. 7).
Accurate determination of the minimum inhibitory concentration (MIC) can prevent adverse side effects, such as
renal toxicity. Considering that the contemporary MIC determination depends on a day-long process, we examined if Au
NPs can yield results faster without sacrificing reliability.
Initially, E. coli (10 6 CFU) were incubated for 2 hours at 37°
C. in MH broth, in the presence of different concentrations of
ampicillin. Then, aliquots of these samples were incubated
with Au NPs for 30 minutes at 25° C., in the presence of Con
A. Based on the shifts of the surface plasmon band, the MIC
was determined to be 8 µg, as the corresponding surface
plasmon band shift was statistically different than the control,
containing bacteria growing in the absence of antibiotic (FIG.
SA). Correlation with standard methods was achieved by
inoculating serial dilutions of ampicillin in MH broth with E.
coli, followed by a 24-hour long incubation at 37° C. Bacterial growth was assessed based on the broth's turbidity,
whereas absence of turbidity was an indicator of successful
antimicrobial susceptibility. The lowest ampicillin concentration where the MH broth was clear, suggesting that no bacteria proliferated, was 8 µg (FIG. SB). This concentration was

5

10

15

20

25

30

35

40

45

50

55

60

65

US 9,057,094 Bl
9

10

identical to the Au NP-determined MIC, though the Au NPbased method yielded the same results much faster.
Finally, the potential of our Au-NP-based assay for the
determination of antimicrobial susceptibility in highthroughput format was investigated. In these studies, samples
ofheat-inactivatedE. coli (10 6 CFU) andE. coli (10 6 CFU)
grown in the presence or absence of ampicillin were screened
with the Au-NP on a 96-well plate using a microtiter plate
reader. Addition of Con A, followed by a 30-min incubation at
25° C., resulted in distinct changes of the surface plasmon
band, similar to those described above (FIG. SA) with standard errors ofless than 0.6 nm. This allowed the categorization of the samples in inhibitory (heat-inactivation and 64 µg
ampicillin) or non-inhibitory (2 and 0 µg ampicillin) cohorts
(FIG. 9), demonstrating the capability of our method to
screen multiple samples and assess various compounds' antimicrobial activity simultaneously in a high-throughput format.
Dextran-Coated Iron Oxide Nanoparticles for Antimicrobial
Susceptibility:
First, we wanted to determine if magnetic IO NPs coated
with dextran could be used to determine and quantify the
levels of a polysaccharide (starch) in bacterial culture media.
Specifically, 190 µl ofIO NPs (9.5 µLnanoparticles [0.685 µg
Fe/µL] in 180.5 µL deionized water) were inoculated with 10
µL specimens of starch-containing growth media. Ten µL of
ConcanavalinA (1 µg/µL) were added, and then the samples
were incubated at room temperature for various time intervals. The samples were examined in a Bruker 0.47 T (20
MHz) magnetic relaxometer (The MiniSpec, Bruker), and the
individual sample's changes in spin-spin relaxation times
(llT2) were determined based on the formula:
Ifl T2incubation time -flT2prior ConA I. The 0 btained data indicated
that the changes in fl T2 depend on the starch concentration,
under concanavalin-induced assembled conditions (FIG. 10 ).
The observed behavior supported the hypothesis that magnetic nanoparticles affect the spin-spin relaxation times of
adjacent water protons in a dose-dependent mamier, associated with the levels of carbohydrates within a solution, under
assembled conditions.
Next, as bacteria utilize carbohydrates in their metabolic
pathways, we hypothesized that any variations in the carbohydrate concentrations attributed to bacterial growth should
be observable, using a known amount of dextran-coated IO
NPs and Con A. Hence, the changes in T2 of the nanoparticles' suspension should have been related to the extent of
carbohydrates consumption by bacteria. Therefore, the more
bacteria present in a suspension the higher the consumption
and depletion of carbohydrates should have been. In order to
test this hypothesis, samples of various CFU loads of logphase E. coli were incubated for 1 hour at 3 7° C. in MH broth,
to allow carbohydrate (starch) consumption. Then, the
samples were autoclaved, and 10 µl aliquots were added to
190 µL of dextran-coated IO NPs (9.5 µL nanoparticles
[0.685 µg Fe/µL] in 180.5 µL deionized water). Before addition of Con A, all samples exhibited the same T2 (FIG. 11).
Addition of Con A (1 µg/µL) induced nano-assembly formation, resulting in dose-dependent changes in T2 (FIG. 12).
The more pronounced changes (higher llT2) were observed
in samples with higher bacterial loads, due to the higher, more
extensive consumption of starch.
In order to determine if indeed the observed differences
were attributed to the consumption of starch, and not to the
populations of bacteria present per se, we incubated various
amounts of E. coli in MH broth with 1.5 mg/mL starch concentration, for 10 minutes at 37° C., in order to prevent bacterial cell division. Immediately after incubation, the samples

were autoclaved, in order to heat inactivate the bacteria and
halt their metabolic reactions. Then, 10 µL aliquots of these
samples were incubated with IO NPs, as described above.
Addition of Con A (1 µg/µL) resulted in nanoassembly formation, yet with no statistically significant differences (FIG.
13). Considering these data, we concluded that the nanoparticle technology can sense the starch levels and bacterial
metabolism, and not the bacteria per se.
Then, utilizing the IO NPs, we determined ampicillin's
MIC. Specifically, E. coli (10 6 CPUs) were incubated for 2
hours at 37° C. in MH broth, in the presence of different
concentrations of ampicillin. Then, 10 µL specimens of these
samples were incubated with IO NPs, as described above. In
the absence of Con A, all samples had identical T2 values,
indicating that the presence of bacteria and antibiotic does not
affect the spin-spin relaxation time of the nanoparticle suspension (FIG. 14). However, in the presence of Con A and
after a 30-minute incubation at room temperature, distinct
changes were observed (FIG. 15A). Specifically, the magnetic-relaxation-determined minimum inhibitory concentration was 8 µg, as at this concentration we observed a drastic
change in the values of llT2. Confirmation of the T2-derived
minimum inhibitory concentration was achieved through the
turbidity test, described before. Notably, both the T2- and
turbidity-derived concentrations were identical (FIG. 15B).
We then determined the antibiotic susceptibility or resistance of other bacteria utilizing the IO NPs. Shigella sonnei
(10 6 CPUs) and Serratia marcescens (10 6 CPUs), grown in
pure cultures, were incubated for 2 hours at 37° C. in MH
broth, in the presence of different concentrations of ampicillin. Ten µL specimens of these samples were incubated with
IO NPs, as described above. In the absence of Con A, all
samples had identical T2 values. Addition of Con A, followed
by a 30-minute incubation at room temperature, resulted in
different patterns between the two microorganisms (FIGS. 16
and 17). Specifically, the magnetic-relaxation-determined
minimum inhibitory concentration was 8 µg for Shigella sonnei (FIG. 16), whereas Serratia marcescens was found to be
resistant to ampicillin, as all samples exhibited similar
changes in the T2 (FIG. 17). Confirmation of the T2-derived
minimum inhibitory concentration was achieved through the
turbidity test, yielding identical results to the T2-mediated
ones.
Lastly, due to the fact that many bacteria can either cause
septicemia or require growth in optically turbid media, it is
important to assess bacterial susceptibility in these complex
matrices. However, most current methods cannot be utilized
for the detection of molecular targets and assessment of antimicrobial susceptibility in blood, due to the strong absorbance and scattering from the matrix's constituents, including platelets and red blood cells. Therefore, considering these
drawbacks and the facts that bacterial isolation is a major
limitation step in diagnosis and that certain pathogenic microorganisms require growth in specialized media, we investigated whether the dextran-coated polysaccharide nanosensors could assess antimicrobial susceptibility in blood.
Recently, we reported the high-throughput bacterial susceptibility determination, using the surface plasmon band shifts
of gold nanoparticles. However, this method cannot be used
in opaque media, such as blood, due to the intrinsic optical
properties of the matrix, masking the nanoparticles' plasmonic band. To investigate this, we usedE. coli and S. marcescens cultures suspended in blood-supplemented MH broth
and incubated in the presence of ampicillin for 2 hours at 3 7°
C. Aliquots of these cultures (10 µL) were obtained and added
into the dextran-coated polysaccharide nanosensors working
solution, followed by 10 µL ConA treatment (1 µg/µL).After
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45 minutes following Con A addition at room temperature,
we determined that the E. coli 's ampicillin MIC was 8 µg,
without observing any nanoparticle precipitation. Additionally, the S. marcescens' drug resistance was identified after an
hour-long incubation at 25° C. These data were published in
the above-referenced paper in Plos One, September 2008,
Vol. 3, Issue 9, e3253;an Internet publication available at
www.plosone.org.
Antimicrobial Susceptibility Assessment Using Concanavalin A-Conjugated Polysaccharide Nano sensors
Often times a slight modification in the nanosensors'
design and/or the protocol followed can result in significant
improvements in either the sensitivity or speed of the assay.
Therefore, we hypothesized whether conjugating Con A to
the surface of the magnetic nanoparticles would allow for
faster kinetics and shorter the detection time. For these
experiments, we conjugated Con A directly to aminated
silica-coated iron oxide nanoparticles. We chose silica-coated
instead of dextran-coated iron oxide nanoparticles to avoid
possible cross reaction with the dextran on the nanoparticle' s
surface. In this non-competition assay (FIG. 18), the Con
A-conjugated silica coated nanosensors would facilitate the
direct sensing of the levels of carbohydrates in solution, as
opposed to the competition assay that requires two reagents;
the dextran-coatednanoparticles and the ConA for successful
sensing. The aminated silica-coated nanoparticles were synthesized using a modified water-based synthetic protocol.
The resulting nanoparticles were monodispersed, having a
diameter of 145 nm and an R2 relaxivity of 225 mM- 1 s- 1 .
In our first set of experiments with the aminated silicacoated nanoparticles, we determined whether these nanoparticles clustered non-specifically in the presence of Con A in
solution. As expected, we observed that Con A did not induce
any changes in the relaxation times of the nanoparticles. This
demonstrates that the silica coating on these nanoparticles
lacks any carbohydrate epitopes, rendering them suitable for
the noncompetition-based sensing of carbohydrates. Therefore, we conjugated Con A to the aminated silica-coated
nanoparticles, via carbodiimide chemistry, resulting in Con
A-carrying nanoparticles with a hydrodynamic diameter of,
160 nm (R2=225 mM- 1 s-1, [ConA]=0.03 µg/µL). First, we
compared the kinetic profiles of the dextran-coated nanosensors and Con A-conjugated nanosensors using bacterial E.
coli blood cultures (106 CFU grown in the presence of 2 µg
ampicillin). Interestingly, we found that the non-competition
assay with the ConA-conjugatednanosensors (FIG.19, curve
B) provided faster results than the competition assay that
utilizes the dextran-coated nanosensors (FIG. 19, curve A).
Specifically, the competition assay format reached its endpoint after a 45-minute incubation, whereas the non-competi ti on assay reaches its end-point within 5 minutes upon addition of the bacterial sample. These findings support our
hypothesis of achieving faster kinetics due to the direct conjugation of Con A to the nanoparticles.
Then, we examined if MIC determination can be achieved
using these Con A-conjugated nano sensors, in blood cultures
of E. coli and S. marcescens. Immediately upon addition of
the bacterial sample into the nanoparticle solution, distinct
changes in the T2 were observed. Specifically, within 5 minutes the Con A nanosensors were able to determine thatE. coli
had an ampicillin MIC of 8 µg (FIG. 20A), in line with the
data from the dextrancoated nanosensors in the competition
assay or the turbidity test. Likewise, within 5 minutes the Con
A-conjugated nanosensors assessed that S. marcescens was

resistant to ampicillin, further corroborating the findings that
the non-competition assay format provides faster results than
the competition-based assay of the dextran-coated nanosensors (FIG. 20B).
The Con A-conjugated polysaccharide nanosensor assay
yields faster results, without compromising sensitivity and
reliability, due to faster binding kinetics. Also, as there is no
need forthe addition of a second reagent (ConA), this format
might be particularly useful for point of-care diagnostics and
applications in the field.
Accordingly, in the drawings and specification there have
been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the
terms are used in a descriptive sense only and not for purposes
of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims.
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That which is claimed:
1. A method of testing bacterial cells for antimicrobial
susceptibility, the method comprising:
mixing a suspension of bacterial cells in a non-nutrient
medium with an antimicrobial and a carbohydrate
usable by the bacterial cells;
adding iron oxide nanoparticles and a lectin to the mixture;
and
monitoring a parameter associated with the nanoparticles
responsive to use of the carbohydrate by the bacterial
cells.
2. The method of claim 1, wherein the antimicrobial comprises a pharmaceutical administrable to a human or animal
patient.
3. The method of claim 1, wherein the iron oxide nanoparticles nanoparticles comprise rod-shaped nanoparticles.
4. The method of claim 1, wherein the lectin is conjugated
to the surface of the iron oxide nanoparticles before adding.
5. The method of claim 1, wherein the iron oxide nanoparticles further comprise a coating polymer which bears the
lectin.
6. The method of claim 1, wherein the iron oxide nanoparticles further comprise a coating of amino-silica bearing the
lectin.
7. The method of claim 1, wherein the iron oxide nanoparticles further comprise a coating polyacrylic acid polymer
bearing the lectin.
8. The method of claim 1, wherein the lectin has a high
binding affinity for the carbohydrate.
9. The method of claim 1, wherein the lectin comprises
concanavalin A.
10. The method of claim 1, wherein the parameter is monitored by nuclear magnetic resonance.
11. The method of claim 1, wherein the parameter is monitored by the nuclear magnetic resonance T2 water relaxation
time.
12. The method of claim 1, wherein the magnetic relaxation parameter comprises an increase or a decrease in T2
water relaxation time by nuclear magnetic resonance.
13. The method of claim 1, wherein the iron oxide nanoparticles are capable of causing an increase or a decrease in
the T2 of water.
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